
Kezar Life Sciences Inc KZR.OQ KZR.O is expected to show no change in quarterly revenue when it reports results on May 7 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for Kezar Life Sciences Inc is for a loss of $2.60 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kezar Life Sciences Inc is $12.50, above its last closing price of $4.30.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -2.59 | -2.88 | -2.77 | Beat | 4 |
Sep. 30 2024 | -3.27 | -3.15 | -2.78 | Beat | 11.7 |
Jun. 30 2024 | -3.39 | -3.20 | -2.70 | Beat | 15.7 |
Mar. 31 2024 | -3.33 | -3.33 | -3.00 | Beat | 9.9 |
Dec. 31 2023 | -4.30 | -3.80 | -4.40 | Missed | -15.8 |
Sep. 30 2023 | -3.58 | -3.49 | -3.20 | Beat | 8.4 |
Jun. 30 2023 | -3.21 | -3.20 | -3.40 | Missed | -6.2 |
Mar. 31 2023 | -2.90 | -2.88 | -3.10 | Missed | -7.5 |
This summary was machine generated May 5 at 22:32 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)